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Opioid use trends in patients undergoing elective 
thoracic and lumbar spine surgery
Background: Opioid use in North America has increased rapidly in recent years. Pre­
operative opioid use is associated with several negative outcomes. Our objectives were to 
assess patterns of opioid use over time in Canadian patients who undergo spine surgery 
and to determine the effect of spine surgery on 1­year postoperative opioid use.
Methods: A retrospective analysis was performed on prospectively collected data from 
the Canadian Spine Outcomes and Research Network for patients undergoing elective 
thoracic and lumbar surgery. Self­reported opioid use at baseline, before surgery and at 
1 year after surgery was compared. Baseline opioid use was compared by age, sex, radio­
logic diagnosis and presenting complaint. All patients meeting eligibility criteria from 
2008 to 2017 were included.
Results: A total of 3134 patients provided baseline opioid use data. No significant change in 
the proportion of patients taking daily (range 32.3%–38.2%) or intermittent (range 13.7%–
22.5%) opioids was found from pre­2014 to 2017. Among patients who waited more than 
6 weeks for surgery, the frequency of opioid use did not differ significantly between the base­
line and preoperative time points. Significantly more patients using opioids had a chief com­
plaint of back pain or radiculopathy than neurogenic claudication (p < 0.001), and significantly 
more were under 65 years of age than aged 65 years or older (p < 0.001). Approximately 41% 
of patients on daily opioids at baseline remained so at 1 year after surgery.
Conclusion: These data suggest that additional opioid reduction strategies are needed 
in the population of patients undergoing elective thoracic and lumbar spine surgery. 
Spine surgeons can be involved in identifying patients taking opioids preoperatively, 
emphasizing the risks of continued opioid use and referring patients to appropriate 
 evidence­based treatment programs.
Contexte : En Amérique du Nord, l’utilisation d’opioïdes a augmenté rapidement dans 
les dernières années. La prise d’opioïdes en période préopératoire est associée à plusieurs 
issues négatives. Cette étude visait à évaluer l’évolution des tendances dans l’utilisation 
d’opioïdes des patients canadiens ayant subi une chirurgie spinale, et de déterminer les 
effets de la chirurgie sur leur utilisation 1 an après l’opération. 
Méthodes : Une analyse rétrospective a été réalisée à partir de données recueillies de 
manière prospective par le Canadian Spine Outcomes and Research Network pour les 
patients ayant subi une chirurgie thoracique ou une chirurgie spinale élective. On a com­
paré l’utilisation autodéclarée d’opioïdes au début du suivi, avant la chirurgie et 1 an 
après la chirurgie. L’utilisation d’opioïdes au départ a été comparée selon le sexe, l’âge, le 
diagnostic radiologique et le motif de consultation. Entre 2008 et 2017, tous les patients 
satisfaisant aux critères d’admissibilités ont été inclus dans l’étude.
Résultats : Au total, 3134 patients ont fourni des données sur leur prise d’opioïdes au 
début du suivi. Il n’y avait pas de changement significatif dans la proportion de patients 
utilisant quotidiennement (32,3 % à 38,2 %) ou occasionnellement (13,7 % à 22,5 %) des 
opioïdes entre les patients à l’étude avant 2014 et ceux à l’étude de 2014 à 2017. Parmi les 
patients qui ont attendu plus de 6 semaines avant la chirurgie, la fréquence de la prise 
d’opioïdes n’a pas changé de manière significative entre le début du suivi et la rencontre 
préopératoire. Une proportion significativement plus grande de patients qui utilisaient des 
opioïdes consultaient principalement pour des douleurs au dos ou une radiculopathie que 
pour une claudication neurogène (p < 0,001), et il y avait une proportion significativement 
plus grande de patients de moins de 65 ans qui utilisaient des opioïdes que de patients de 
65 ans ou plus (p < 0,001). Environ 41 % des patients qui prenaient quotidiennement des 
opioïdes au départ le faisaient aussi 1 an après la chirurgie.
Conclusion : Ces données suggèrent que des stratégies supplémentaires de réduction de 
l’utilisation d’opioïdes sont nécessaires pour les patients qui subissent une chirurgie thora­
cique ou une chirurgie spinale élective. Il est possible de demander aux chirurgiens spécialisés 
dans ce domaine de repérer les patients qui prennent des opioïdes avant l’opération, puisque 
l’utilisation prolongée comporte des risques, et de les aiguiller vers un programme de traite­
ment adéquat et fondé sur des données probantes.
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O pioid use has increased rapidly in the last 20 years in the United States and Canada.1–3 While previous studies have suggested opioids 
are safe and efficacious in patients with spine pathol­
ogy,4–6 many health­related and socioeconomic prob­
lems associated with opioid use have become apparent. 
Recent research in patients who undergo hip and knee 
arthroplasty and spinal procedures has indicated that 
patients on preoperative opioids have more difficulty 
with pain control in the perioperative period,7,8 
increased hospital length of stay (LOS)9 and worse 
postoperative outcomes than patients not regularly 
using opioids preoperatively.10–13
It is estimated that nearly one­quarter of patients who 
undergo orthopedic surgery and 19% of patients who 
undergo neurosurgery are on opioids preoperatively.14 In 
Canada, there is a lack of research documenting the pro­
portion of patients presenting to tertiary spine surgery 
clinics who are taking opioids. To our knowledge, no 
publication has investigated whether increased physician 
awareness of the adverse effects associated with regular 
opioid usage has resulted in fewer patients being pre­
scribed opioids for spine­related pain.
Recent clinical guidelines have recommended against 
opioid use for the management of low­back pain.15 A 
recent randomized controlled trial indicated that treat­
ment with opioids was not superior to treatment with 
nonopioid medications for improving pain­related func­
tion over 12 months in patients with moderate to severe 
chronic back pain.16
The aims of this study were to determine the propor­
tion of patients presenting to tertiary spine surgery clin­
ics in Canada who indicated opioid use, examine trends 
over time and investigate 1­year postoperative opioid 
use. Ultimately, our goal was to evaluate the need for 
surgeons to be proactive in addressing opioid use and 
reducing harms associated with opioid prescribing.17 The 
authors hypothesize that, owing to the increase in media 
attention regarding opioid use and physician awareness 
of associated risks, a decrease in opioid use will be 
observed during the study period.
Methods
Study design
We conducted a multicentre, retrospective review of 
consecutive patients undergoing thoracic and lumbar 
spine surgery who were enrolled by the Canadian 
Spine Outcomes and Research Network (CSORN) 
between October 2008 and August 2017. The network 
is a group of more than 50 neurosurgical and orthope­
dic spine surgeons from 18 tertiary care academic and 
non academic hospitals across Canada that prospec­
tively collects data on patients with spinal conditions 
on an ongoing and voluntary basis. This database 
serves as a national registry, which was created to 
answer research questions and to facilitate the imple­
mentation of best practices.
A national database research coordinator audits 
data quality and performance and sends reports to 
each contributing hospital site coordinator on a 
quarterly basis. Reports track data completion and 
follow­up rates to facilitate internal data validation at 
each site. A national privacy and security framework 
was created for CSORN that includes a governance 
structure, standard operating procedures, training 
processes, physical and technical security and privacy 
impact assessments. This model ensures that personal 
health information is kept private and secure. Writ­
ten informed consent is obtained from all partici­
pating patients. Patient information is anonymized to 
ensure that patients in the network cannot be indi­
vidually identified. Twelve sites contributed to this 
specific project. Each site obtained research ethics 
board approval before any data collection. Decisions 
regarding data collection, storage and analysis are 
independent of any particular company or commer­
cial interest.
Patient sample
Local research coordinators enrolled eligible patients 
at each site. To be eligible, patients had to be 18 years 
of age or older and must have undergone elective sur­
gery involving the thoracic and/or lumbar spine 
(decompression or decompression and fusion) and 
answered the question pertaining to opioid pain medi­
cation on the baseline questionnaire. Exclusion cri­
ter ia were as follows: emergency cases, fractures, revi­
sion surgery, tumour, surgery at cervical levels and a 
chief complaint other than back pain, neurogenic clau­
dication and/or radiculopathy. Chief complaint was 
documented by the surgeon at the time the surgical 
procedure was booked. Patients were asked to report 
opioid use at the initial visit with a spine surgeon 
(baseline), preoperatively (if the surgical date was 
more than 6 weeks after the initial visit) and at 1­year 
post operative follow­up.
Patient variables
Baseline preoperative patient characteristics included 
sociodemographic factors, use of opioid and nonopioid 
medications, comorbidities, symptom duration and 
symptom intensity. The specific focus of this study was 
on the question “Do you take opioid pain medication 
for your back problem?” Examples of generic opioids 
were provided. The response choices were “never,” 
“intermittent” or “daily.”
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Study measures
The treating surgeons recorded operative and postop­
erative variables including type of procedure, number 
of levels, chief complaint and primary radiologic diag­
nosis.  Research coordinators collected patient­
reported outcomes and information on medication use 
at baseline, preoperatively (>  6 wk from baseline, 
before surgery) and 12 months postoperatively. The 
additional preoperative data point was reported by 
only 5 of the 12 sites because of limitations in the 
availability of staff resources. Data were collected in 
person, via post or through an emailed hyperlink to an 
online patient portal.
Statistical analysis
The registry started as a pilot at 1 site in 2008, expanded 
to 3 sites in 2012 and gradually grew over the subse­
quent years to encompass 18 sites; patients who had sur­
gery between 2008 and 2013 were grouped together for 
the analysis owing to the relatively small number of 
patients in the early years of the database. Opioid use 
was stratified by year (pre­2014, then annually through 
to and including 2017) at baseline, preoperatively in 
those patients who waited longer than 6 weeks after 
their initial visit for surgery, at 1 year postoperatively, 
and by chief complaint, age and primary radiologic 
diagnosis. χ2 testing, with significance set a priori at 5%, 
was used to compare opioid use by enrolment year, time 
point (baseline presentation, preoperative and 1­year 
postoperative), sex, age, symptom duration, radiologic 
diagnosis and chief complaint. Patients with both base­
line and preoperative data were compared using paired­
samples t tests to assess the impact of an extended wait 
time before surgery.
Results
Of the 4267 patients who met the inclusion criteria, 
26.6% did not provide complete baseline data on opi­
oid use. Thus, the evaluated sample was 3134 patients. 
There were no differences in age, sex, number of lev­
els or symptom duration between patients who 
answered the question on opioid use and those who 
did not. Table 1 provides baseline characteristics for 
the sample population.
A total of 34.5% of the patients reported daily opi­
oid use, 19.8% intermittent use and 45.8% no opioid 
use. There was no change in the proportion of opioid 
use over time (p = 0.39; Fig.  1): the proportion of 
patients taking opioids daily ranged from 32.3% to 
38.2%, and the proproportion of patients taking opi­
oids intermittently ranged from 13.7% to 22.5%. 
There was no significant difference in opioid use by 
sex: 36.5% of women used opioids daily, 20.7% used 
them intermittently and 42.8% never used them, 
whereas 32.4% of men used opioids daily, 18.9% used 
them intermittently and 48.8% never used them (p = 
0.42). There was also no significant difference in opi­
oid use by symptom duration: 43.7% of patients who 
had had symptoms for less than 2 years and 46.7% of 
patients who had had symptoms for 2 or more years 
never used opioids (p = 0.11). Significantly more 
patients under age 65 years were taking opioids, com­
pared with those aged 65 years or older (p < 0.001; 
Fig.  2). Significantly fewer patients with a chief com­
plaint consistent with neurogenic claudication were 
taking opioid medications than those with radiculo­
pathy or back pain (p < 0.001; Fig. 3).
Table 1. Baseline characteristics of patients
Characteristic
Patients who did 
not use opioids
Patients who used 
opioids
Sex, % male 54.3 48.3
Age, yr, mean ± SD (range) 60.8 ± 14.4 (18–89) 56.2 ± 14.5 (18–89)
Age, % of patients
    < 65 yr 52.9 67.9
    ≥ 65 yr 47.1 32.1
Diagnosis, % of patients
    Deformity 4.6 4.3
    Degenerative disc disease 5.1 9.0
    Disc herniation 17.2 27.6
    Spondylolisthesis 37.3 28.8
    Stenosis 35.8 30.3
Chief complaint, % of patients
    Back pain 11.5 14.8
    Neurogenic claudication 46.5 34.0
    Radiculopathy 42.0 51.1
Type of surgery, % of patients
    Decompression alone 38.3 33.5
    Decompression and fusion 61.7 66.5
No. of surgical levels,  
% of patients
    1 63.6 61.8
    2 21.7 21.6
    ≥ 3 14.6 16.6
No. of comorbidities,  
% of patients
    0 10.3 6.5
    1 21.8 19.6
    2 22.6 20.3
    ≥ 3 45.3 53.6
Symptom duration,  
% of patients
    < 1 yr 18.6 23.3
    1–2 yr 16.2 14.3
    ≥ 2 yr 65.2 62.4
Numeric pain rating,  
mean ± SD (range)
    Back 6.42 ± 2.45 (0–10) 7.28 ± 2.13 (0–10)
    Leg 7.06 ± 2.26 (0–10) 7.5 ± 2.1 (0–10)
SD = standard deviation.
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Significantly more patients with a primary radio­
logic diagnosis of degenerative disc disease were taking 
opioids (67.6%) than those with a primary diagnosis of 
deformity, spondylolisthesis or stenosis (p < 0.01; 
Fig.  4). Similarly, significantly more patients with a 
primary radiologic diagnosis of disc herniation 
reported taking opioids (65.4%) than those with a pri­
mary diagnosis of deformity, spondylolisthesis or sten­
osis (p < 0.01; Fig. 4).
At 5 of the 12 sites, updated questionnaires were 
administered to patients who waited longer than 6 weeks 
for surgery. Analysis of these data (for 895 patients) 
revealed no significant difference in the proportions of 
opioid use between the baseline and preoperative time 
points (at baseline 37.2% of patients reported daily use, 
21.9% reported intermittent use and 41.0% reported no 
use of opioids; at the preoperative time point 36.8% 
reported daily use, 21.6% reported intermittent use and 
41.7% reported no use of opioids; p > 0.05).
Of the 3134 patients in this study, 2329 passed the 
1­year mark from surgery and were eligible for 1­year 
follow­up; 1624 were reached for follow­up (69.7%). 
Within this cohort, at 1­year postoperative follow­up 
there was a significant decrease in the proportion of 
patients taking daily opioids from baseline (34.7% to 
16.9%, p < 0.01) and an increase in the proportion of 
patients not taking opioids (45.8% to 71.4%, p < 0.01; 
Fig. 5). Of the patients not taking opioids at baseline, at 
1­year follow­up, 3.9% reported taking opioids daily and 
5.4% intermittently; 676 (90.7%) did not take opioids at 
baseline nor at 1­year follow­up. 
Of the patients taking intermittent 
or daily opioids at baseline, 54.7% 
reported taking no opioids at 
1­year follow up. Of the patients 
who took opioids daily at baseline, 
13.8% went down to intermittent 
use and 45.7% reported taking no 
opioids at 1­year follow­up.
discussion
With data from the CSORN, we 
investigated the proportions of 
patients undergoing spine sur­
gery who used opioids and the 
concomitant changes in opioid 
use over time. Fifty­two percent 
of patients presenting to Canad­
ian tertiary spine surgery clinics Fig. 1. Opioid use at baseline by year. 
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Fig. 2. Opioid use at baseline by age. *Denotes significant differ-
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Fig. 3. Opioid use at baseline by chief complaint. *Denotes sig-
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before 2014 reported taking opioids on a daily or 
intermittent basis, a finding that was relatively con­
sistent across the study period (2008 to 2017). We 
found that significantly fewer patients aged 65 years 
and older took preoperative opioids than patients 
younger than 65 years of age. This is probably attrib­
utable to the finding that fewer patients with a radio­
logic diagnosis of stenosis and chief complaint of 
neurogenic claudication were on preoperative opioids 
than those with other diagnoses, and neurogenic 
claudication secondary to stenosis is more common 
in older patients (average age at the time of surgery 
was 63.8 yr in a Canadian cohort, as compared with 
35.8 yr for radiculopathy).18,19 Another possible rea­
son for the difference in opioid use by age is that 
neurogenic claudicat ion symptoms tend to be 
relieved with rest and many patients do not take 
analgesics for this problem; rather, they modify their 
activities to control symptoms.
At 1 year after surgery, 
daily opioid use among our 
patient population was signifi­
cantly lower than at the time 
of the initial visit with the 
spine surgeon;  however , 
almost 30% of patients con­
tinued to take opioids on a 
daily or intermittent basis. 
Nearly half of patients (45%) 
who were taking opioids 
before surgery remained on 
opioids at 1­year follow­up, 
and, alarmingly, nearly 10% 
of patients who were opioid 
naïve before surgery were 
found to be taking opioids 
1 year after surgery.
A recent study by Dunn 
and colleagues investigated 
opioid use in patients undergoing elective spinal fusion 
of 2 levels or more at a university hospital in the United 
States.20 They found that 72% of patients were taking 
opioids before surgery. In comparison, 54% of patients 
in our study were taking opioids at the first assessment 
with a spine surgeon. The greater proportion of 
patients taking opioids preoperatively in the study by 
Dunn and colleagues may reflect a difference in inclu­
sion criteria (i.e., all elective thoracic and lumbar sur­
gery cases versus elective spinal fusions of 2 levels or 
more). Nonetheless, 52% of those patients taking opi­
oids preoperatively were still taking opioids at 1­year 
follow­up, which is similar to the follow­up findings of 
our study.20
Pugely and colleagues studied patients in the 
United States undergoing cervical spine fusion 
between 2007 and 2014 and found that 52% were 
taking opioids before surgery.21 At 1­year follow­up, 
45% of patients who had used opioids preopera­
tively remained on opioids. Both of these results are 
comparable to the findings of our study. Further­
more, the authors found preoperative opioid use was 
associated with an increased likelihood of postoper­
ative opioid use after 12 months, a finding consis­
tent with several studies in patients who undergo 
spine surgery.7,21,22
Regular opioid use in patients who undergo spine 
surgery is concerning for many reasons, with reported 
associations including inferior clinical outcomes, lower 
return to work rates, increased pain intensity in the 
perioperative period and increased hospital LOS.8–11,23 
Our results indicate that approximately 45% of preop­
erative opioid users remained on opioids 1 year after 
their spine surgery. Given this result and the fact that 
preoperative opioid use is a risk factor for continued 
Fig. 5. Opioid use at baseline versus 1 year postoperatively.






























Fig. 4. Opioid use at baseline by primary diagnosis. Patients in the stenosis category did not 
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use at 1 year after surgery, there is a need for opioid 
reduction strategies and for spine surgeons to assist in 
efforts to decrease opioid use preoperatively.
Limitations
Our study relied heavily on data from patient self­
administered questionnaires, and it is therefore subject 
to limitations inherent to such surveys, including 
skipped answers and misunderstood questions.24 Our 
analysis is also limited to those patients who admitted to 
taking opioids for their back problem. It is possible that 
a proportion of patients may have chosen not to answer 
this question because of a perceived stigma associated 
with opioid use. This limitation may have led to an 
underreporting bias of opioid use in our patient sample. 
Conversely, it is possible that our study overreports the 
proportion of patients using opioids by excluding those 
who did not specifically answer “none” to the opioids 
question even though they were not taking opioids. Fur­
thermore, we do not have data on the quantity or dose 
of opioids taken by the patients included in this study. A 
1­year follow­up rate of 70% is another limitation. It is 
possible that many patients for whom we do not have 
data at 1 year could have been uncontactable because 
they were doing well and were no longer seeking med­
ical treatment. However, there are several possible rea­
sons for losing patients to follow­up regardless of their 
condition. including unwillingness of the patient to be 
contacted, a change in contact information or failure of 
correspondence.
conclusion
The prevalence of opioid use in patients who undergo 
spine surgery in Canada remains high, with nearly half 
of patients who take opioids before surgery remaining 
on these medications 1 year after their procedure. There 
is an opportunity to improve clinical outcomes by 
decreasing opioid use in this population. Spine surgeons 
may have a role to play in identifying patients taking 
opioids preoperatively, helping to emphasize the risks of 
continued opioid use and referring patients to appropri­
ate evidence­based treatment programs. 
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